Spyre Therapeutics (SYRE) Non-Current Assets (2015 - 2025)

Spyre Therapeutics has reported Non-Current Assets for 11 years, with the latest figure at $10000.0 in Q1 2025.

• For the quarter ending Q1 2025, Non-Current Assets fell 96.96% year-over-year to $10000.0; the trailing twelve-month figure through Dec 2025 stood at $10000.0 (down 98.53% YoY), and the FY2024 full-year result was $10000.0, down 96.98% from the prior year.
• Non-Current Assets for Q1 2025 stood at $10000.0, roughly flat from $10000.0 in the prior quarter.
• The five-year high for Non-Current Assets was $12.6 million in Q2 2021, with the low at $10000.0 in Q3 2024.
• Historically, Non-Current Assets has averaged $5.9 million across 5 years, with a median of $8.1 million in 2023.
• Annual changes were most pronounced in 2021 — Non-Current Assets climbed 16.03% — and 2024, when it slumped 99.24%.
• Spyre Therapeutics' Non-Current Assets stood at $11.0 million in 2021, then dropped by 19.47% to $8.9 million in 2022, then plunged by 96.28% to $331000.0 in 2023, then plunged by 96.98% to $10000.0 in 2024, then changed by 0.0% to $10000.0 in 2025.
• The last three Non-Current Assets figures came in at $10000.0 (Q1 2025), $10000.0 (Q4 2024), and $10000.0 (Q3 2024), per Business Quant data.